Omalizumab decreases colds in inner-city children with asthma, study reports

March 6, 2016, NIH/National Institute of Allergy and Infectious Diseases

Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2016 Annual Meeting in Los Angeles. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids.

These findings are a secondary result from the Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE) study conducted through the Inner-City Asthma Consortium (ICAC). ICAC is an asthma research program supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

In this randomized trial, researchers gave 478 children living in cities throughout the United States three types of during the fall, a season when colds are common and tend to worsen. The control group received guidelines-based asthma care, while two additional groups received this care with additional treatment of either fluticasone or omalizumab. Fluticasone is an inhaled corticosteroid sold under the brand name Flovent. The children's caregivers then monitored them for cold symptoms, such as runny nose, cough and sore throat. Based on these reports, researchers identified a total of 1,034 symptomatic colds and found that children who received omalizumab experienced a 27 percent decrease in cold incidence compared to children receiving only guidelines-based asthma care. Children who received fluticasone did not experience a significant change in cold incidence.

This study builds upon previous ICAC studies that showed that long- and short-term treatment with omalizumab decreases seasonal attacks in inner-city 6 to 17 years of age. Researchers do not yet know how omalizumab decreases colds in this specific population. However, research shows that omalizumab targets and reduces levels of an antibody known as immunoglobulin E, or IgE. Data from previous studies indicate that lower IgE levels are associated with higher interferon responses, which are known to be important in protecting against viruses, such as those that cause cold symptoms.

Explore further: New research on preventing fall asthma exacerbations

Related Stories

New research on preventing fall asthma exacerbations

January 14, 2016
Experts from Children's Hospital Colorado (Children's Colorado) co-led a team of researchers in studying new approaches to reducing fall asthma exacerbations in pediatric patients. Their findings were released online in late ...

Biologics for asthma: Attacking the source of the disease, not the symptoms

November 5, 2015
Imagine you suffer from severe asthma, and you've tried every treatment available, but nothing has worked. You still can't breathe. Then a new therapy comes along that attacks the source of the asthma, as opposed to the symptoms, ...

Better targeting of treatment gives hope to people with severe asthma

March 2, 2016
Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. ...

Common colds at school a primary driver of asthma hospitalizations for children

February 8, 2016
The most dangerous times of year for children with asthma are soon after their schools reopen after a break, and a new study finds that cold viruses are largely to blame.

New inhaled drug shows promise against asthma, allergies

July 2, 2014
A new inhaled medication has the potential to treat mild asthma and allergies by interrupting the production of an immune system protein that triggers allergic reactions, a new study reports.

Recommended for you

The 'greying' of T cells: Scientists pinpoint metabolic pathway behind age-related immunity loss

December 13, 2018
The elderly suffer more serious complications from infections and benefit less from vaccination than the general population. Scientists have long known that a weakened immune system is to blame but the exact mechanisms behind ...

Scientists create most accurate tool yet developed to predict asthma in young children

December 13, 2018
Scientists at Cincinnati Children's Hospital Medical Center have created and tested a decision tool that appears to be the most accurate, non-invasive method yet developed to predict asthma in young children.

New genetic study could lead to better treatment of severe asthma

December 12, 2018
The largest-ever genetic study of people with moderate-to-severe asthma has revealed new insights into the underlying causes of the disease which could help improve its diagnosis and treatment.

Researchers discover unique immune cell likely drives chronic inflammation

December 11, 2018
For the first time, researchers have identified that an immune cell subset called gamma delta T cells that may be causing and/or perpetuating the systemic inflammation found in normal aging in the general geriatric population ...

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.